Search Results

Australian biotech company Noxopharm (ASX:NOX) has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to Veyonda ® , its lead oncology drug candidate , for use in the treatment of soft tissue sarcoma.

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has announced its DARRT-2 Phase 2 clinical trial has commenced with patient enrollment in the U.S.

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has in-licensed novel RNA technology developed by Hudson Institute of Medical Research,

Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) today announced its CEP-2 study will begin shortly. CEP-2 is related to the Investigational New Drug (IND) approval of Veyonda ® by the FDA based on evidence that Veyonda may increase generally poor response rates of sarcoma cancers to chemotherapy

Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19, interim data in its NOXCOVID study suggests Veyonda provides protection against progression of the severe inflammation associated with a worsening of the disease.

Noxopharm Pre-clinical Study Confirms Survival Advantage of Combination LuPSMA Therapy in Prostate Cancer

Noxopharm Files Septic Shock Treatment Patent for Veyonda ® New indication doubles the commercial opportunity

Australian clinical-stage drug development company, Noxopharm (ASX: NOX), is pleased to announce that a discovery by Weill Cornell Medical College in New York, recently published in the prestigious scientific journal, Nature Immunology, significantly validates the novel DARRT anti-cancer treatment of its drug candidate, Veyonda®,

Noxopharm (ASX:NOX) has reported preclinical data that further supports the role of experimental anti-cancer drug, idronoxil, the active ingredient in Veyonda® , as an anti-inflammatory drug for early-stage COVID-19 treatments.

Australian clinical-stage drug development company Noxopharm (ASX:NOX) has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda®), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate COVID-19 disease.